LIGHTSITE II Randomized Multicenter Trial: Evaluation of Multiwavelength Photobiomodulation in Non-exudative Age-Related Macular Degeneration

Overview

Journal Ophthalmol Ther

Specialty Ophthalmology

Date 2023 Jan 1

PMID 36588113

Authors

Ben Burton

Maurizio Battaglia Parodi

Ignasi Jurgens

Xavier Zanlonghi

Dan Hornan

Johann Roider

Katrin Lorenz

Marion R Munk

Cindy L Croissant

Stephanie E Tedford

Michael Walker

Rene Ruckert

Clark E Tedford

Affiliations

Soon will be listed here.

Abstract

Introduction: Photobiomodulation (PBM) represents a potential treatment for non-exudative age-related macular degeneration (AMD). PBM uses wavelengths of light to target components of the mitochondrial respiratory chain to improve cellular bioenergetic outputs. The aim of this study was to further investigate the effects of PBM on clinical, quality of life (QoL) and anatomical outcomes in subjects with intermediate stage non-exudative AMD.

Methods: The multicenter LIGHTSITE II study was a randomized clinical trial evaluating safety and efficacy of PBM in intermediate non-exudative AMD. The LumiThera Valeda® Light Delivery System delivered multiwavelength PBM (590, 660 and 850 nm) or sham treatment 3 × per week over 3-4 weeks (9 treatments per series) with repeated treatments at baseline (BL), 4 and 8 months. Subjects were enrolled with 20/32 to 20/100 best-corrected visual acuity (BCVA) and no central geographic atrophy (GA) within the central fovea (500 μm).

Results: LIGHTSITE II enrolled 44 non-exudative AMD subjects (53 eyes). PBM-treated eyes showed statistically significant improvement in BCVA at 9 months (n = 32 eyes, p = 0.02) with a 4-letter gain in the PBM-treated group versus a 0.5-letter gain in the sham-treated group (ns, p < 0.1) for patients that received all 27 PBM treatments (n = 29 eyes). Approximately 35.3% of PBM-treated eyes showed ≥ 5-letter improvement at 9 months. Macular drusen volume was not increased over time in the PBM-treated group but did show increases in the sham-treated group. While PBM and sham groups both showed GA lesion growth in the trial period, there was 20% less growth in the PBM group over 10 months, suggesting potential disease-modifying effects. No safety concerns or signs of phototoxicity were observed.

Conclusion: These results confirm previous clinical testing of multiwavelength PBM and support treatment with Valeda as a novel therapy with a unique mechanism of action as a potential treatment for non-exudative AMD.

Trial Registration: Clinicaltrial.Gov Registration Identifier: NCT03878420.

Citing Articles

Effect of Photobiomodulation on Proliferative Changes in the Retina: Evidence from an In Vitro Model of PVR.

Watson O, Aggio-Bruce R, Essex R, Valter K Adv Exp Med Biol. 2025; 1468:195-200.

PMID: 39930195 DOI: 10.1007/978-3-031-76550-6_32.

Light buckets and laser beams: mechanisms and applications of photobiomodulation (PBM) therapy.

Frankowski D, Ferrucci L, Arany P, Bowers D, Eells J, Gonzalez-Lima F Geroscience. 2025; .

PMID: 39826026 DOI: 10.1007/s11357-025-01505-z.

Short-Term Results of Multiwavelength Photobiomodulation in Retinitis Pigmentosa.

Siqueira R, Pinho T, Brandao C Clin Ophthalmol. 2024; 18:3715-3724.

PMID: 39691309 PMC: 11651134. DOI: 10.2147/OPTH.S483722.

Photobiomodulation in Ophthalmology: A Comprehensive Review of Bench-to-Bedside Research and Clinical Integration.

Garg D, Daigavane S Cureus. 2024; 16(9):e69651.

PMID: 39429338 PMC: 11488463. DOI: 10.7759/cureus.69651.

Reply.

Boyer D, Boyer D, Munk M, Tedford S, Croissant C, Ruckert R Retina. 2024; 44(12):e83-e87.

PMID: 39312884 PMC: 11559959. DOI: 10.1097/IAE.0000000000004266.

References

Hamblin M . Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation. Photochem Photobiol. 2017; 94(2):199-212. PMC: 5844808. DOI: 10.1111/php.12864. View

Ding X, Patel M, Chan C . Molecular pathology of age-related macular degeneration. Prog Retin Eye Res. 2008; 28(1):1-18. PMC: 2715284. DOI: 10.1016/j.preteyeres.2008.10.001. View

Yehoshua Z, Rosenfeld P, Gregori G, Penha F . Spectral domain optical coherence tomography imaging of dry age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2010; 41 Suppl:S6-S14. DOI: 10.3928/15428877-20101031-19. View

Ivandic B, Ivandic T . Low-level laser therapy improves vision in patients with age-related macular degeneration. Photomed Laser Surg. 2008; 26(3):241-5. DOI: 10.1089/pho.2007.2132. View

Abdelfattah N, Zhang H, Boyer D, Rosenfeld P, Feuer W, Gregori G . Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye. Invest Ophthalmol Vis Sci. 2016; 57(4):1839-46. DOI: 10.1167/iovs.15-18572. View

da Silva P, Dos Anjos L, Abduch T, Pereira R, da Fonseca A, de Paoli F . Photobiomodulation can alter mRNA levels cell death-related. Lasers Med Sci. 2019; 34(7):1373-1380. DOI: 10.1007/s10103-019-02732-5. View

Folgar F, Yuan E, Sevilla M, Chiu S, Farsiu S, Chew E . Drusen Volume and Retinal Pigment Epithelium Abnormal Thinning Volume Predict 2-Year Progression of Age-Related Macular Degeneration. Ophthalmology. 2015; 123(1):39-50.e1. DOI: 10.1016/j.ophtha.2015.09.016. View

Wong-Riley M, Liang H, Eells J, Chance B, Henry M, Buchmann E . Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase. J Biol Chem. 2004; 280(6):4761-71. DOI: 10.1074/jbc.M409650200. View

Ivandic B, Ivandic T . Low-level laser therapy improves visual acuity in adolescent and adult patients with amblyopia. Photomed Laser Surg. 2012; 30(3):167-71. DOI: 10.1089/pho.2011.3089. View

10.

Cheng Y, Du Y, Liu H, Tang J, Veenstra A, Kern T . Photobiomodulation Inhibits Long-term Structural and Functional Lesions of Diabetic Retinopathy. Diabetes. 2017; 67(2):291-298. PMC: 5780063. DOI: 10.2337/db17-0803. View

11.

Passarella S, Karu T . Absorption of monochromatic and narrow band radiation in the visible and near IR by both mitochondrial and non-mitochondrial photoacceptors results in photobiomodulation. J Photochem Photobiol B. 2014; 140:344-58. DOI: 10.1016/j.jphotobiol.2014.07.021. View

12.

Ivandic B, Ivandic T . Low-level laser therapy improves vision in a patient with retinitis pigmentosa. Photomed Laser Surg. 2014; 32(3):181-4. DOI: 10.1089/pho.2013.3535. View

13.

Holz F, Sadda S, Busbee B, Chew E, Mitchell P, Tufail A . Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. JAMA Ophthalmol. 2018; 136(6):666-677. PMC: 6145777. DOI: 10.1001/jamaophthalmol.2018.1544. View

14.

Markowitz S, Devenyi R, Munk M, Croissant C, Tedford S, Ruckert R . A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION. Retina. 2019; 40(8):1471-1482. PMC: 7392581. DOI: 10.1097/IAE.0000000000002632. View

15.

Ferraresi C, Parizotto N, de Sousa M, Kaippert B, Huang Y, Koiso T . Light-emitting diode therapy in exercise-trained mice increases muscle performance, cytochrome c oxidase activity, ATP and cell proliferation. J Biophotonics. 2014; 8(9):740-54. PMC: 4422786. DOI: 10.1002/jbio.201400087. View

16.

Gopalakrishnan S, Mehrvar S, Maleki S, Schmitt H, Summerfelt P, Dubis A . Photobiomodulation preserves mitochondrial redox state and is retinoprotective in a rodent model of retinitis pigmentosa. Sci Rep. 2020; 10(1):20382. PMC: 7684292. DOI: 10.1038/s41598-020-77290-w. View

17.

Eells J, Gopalakrishnan S, Valter K . Near-Infrared Photobiomodulation in Retinal Injury and Disease. Adv Exp Med Biol. 2015; 854:437-41. DOI: 10.1007/978-3-319-17121-0_58. View

18.

Tang J, Herda A, Kern T . Photobiomodulation in the treatment of patients with non-center-involving diabetic macular oedema. Br J Ophthalmol. 2014; 98(8):1013-5. PMC: 4106479. DOI: 10.1136/bjophthalmol-2013-304477. View

19.

Albarracin R, Eells J, Valter K . Photobiomodulation protects the retina from light-induced photoreceptor degeneration. Invest Ophthalmol Vis Sci. 2011; 52(6):3582-92. DOI: 10.1167/iovs.10-6664. View

20.

Kauppinen A, Paterno J, Blasiak J, Salminen A, Kaarniranta K . Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci. 2016; 73(9):1765-86. PMC: 4819943. DOI: 10.1007/s00018-016-2147-8. View